<?xml version='1.0' encoding='utf-8'?>
<document id="22116286"><sentence text="Inhibition of CYP3A4 and CYP2C9 by podophyllotoxin: implication for clinical drug-drug interactions."><entity charOffset="35-50" id="DDI-PubMed.22116286.s1.e0" text="podophyllotoxin" /></sentence><sentence text="Podophyllotoxin (PPT) and its derivatives exert significant anti-cancer activities, and one derivative etoposide is often utilized to treat various cancers in the clinic"><entity charOffset="0-15" id="DDI-PubMed.22116286.s2.e0" text="Podophyllotoxin" /><entity charOffset="17-20" id="DDI-PubMed.22116286.s2.e1" text="PPT" /><entity charOffset="103-112" id="DDI-PubMed.22116286.s2.e2" text="etoposide" /><pair ddi="false" e1="DDI-PubMed.22116286.s2.e0" e2="DDI-PubMed.22116286.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22116286.s2.e0" e2="DDI-PubMed.22116286.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22116286.s2.e0" e2="DDI-PubMed.22116286.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22116286.s2.e1" e2="DDI-PubMed.22116286.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22116286.s2.e1" e2="DDI-PubMed.22116286.s2.e2" /></sentence><sentence text=" The aim of the present study is to investigate the inhibitory effects of PPT on major cytochrome P450 (CYP) isoforms in human livers"><entity charOffset="74-82" id="DDI-PubMed.22116286.s3.e0" text="PPT" /></sentence><sentence text=" Inhibition of CYP3A4, CYP2C9, CYP2C8, CYP2D6, CYP2E1 and CYP2A6 by PPT was investigated in the human liver microsomal system"><entity charOffset="68-70" id="DDI-PubMed.22116286.s4.e0" text="PPT" /></sentence><sentence text=" Time-dependent inhibition of CYP3A4 by PPT was also evaluated"><entity charOffset="40-42" id="DDI-PubMed.22116286.s5.e0" text="PPT" /></sentence><sentence text=" The results showed that PPT strongly exhibited inhibitory effects on CYP3A4 and CYP2C9 in a concentration-dependent manner"><entity charOffset="25-27" id="DDI-PubMed.22116286.s6.e0" text="PPT" /></sentence><sentence text=" Half inhibition concentration (IC50) was 1" /><sentence text="1 +/- 0" /><sentence text="3 and 4" /><sentence text="6 +/- 0" /><sentence text="3 meu M for CYP3A4 and CYP2C9, respectively" /><sentence text=" Inhibition kinetic analysis showed that PPT exhibited competitive inhibition towards CYP3A4 and CYP2C9 with Ki of 1"><entity charOffset="41-43" id="DDI-PubMed.22116286.s12.e0" text="PPT" /></sentence><sentence text="6 and 2" /><sentence text="0 meu M, respectively" /><sentence text=" Additionally, PPT exerted time-dependent inhibition towards CYP3A4 and the kinetic parameters were 4"><entity charOffset="15-17" id="DDI-PubMed.22116286.s15.e0" text="PPT" /></sentence><sentence text="4+/- 2" /><sentence text="1 meu M and 0" /><sentence text="06 +/- 0" /><sentence text="01 min-1 for KI and kinact, respectively" /><sentence text=" Our experimental data indicate that potential drug-drug interaction (DDI) might exist when PPT is co-administered with the substrates which mainly undergo CYP3A4- or CYP2C9-mediated metabolism"><entity charOffset="92-94" id="DDI-PubMed.22116286.s20.e0" text="PPT" /></sentence><sentence text="" /></document>